Polestar stock drops despite “best year ever” sales; Feb. 18 update is next test

Polestar stock drops despite “best year ever” sales; Feb. 18 update is next test

New York, Jan 9, 2026, 15:56 EST — Regular session

Polestar Automotive Holding UK PLC shares fell 5.9% to $20.90 at 3:56 p.m. EST, swinging between $20.81 and $22.35 in Friday’s Nasdaq session. In an SEC filing, the electric-vehicle maker put 2025 retail sales at about 60,119 cars, up 34%, and said fourth-quarter volumes rose 27% to 15,608; it said the figures were preliminary and could be adjusted. CEO Michael Lohscheller called 2025 its “best year ever” for retail volumes and set Feb. 18 for a strategy update; Polestar said a December ADS ratio change — akin to a reverse stock split that bundles shares to lift the quoted price — restored compliance with Nasdaq’s $1 bid-price rule.

The sales snapshot lands at a tricky moment for the stock. Polestar has been trying to calm nerves after a long stretch where funding questions and listing mechanics mattered as much as cars.

Polestar has leaned harder on Europe over the past year, with the region now accounting for about 78% of sales as demand cooled and competition sharpened in the United States and China. “Europe is absolutely the core,” Lohscheller told Reuters, as the company shifted from an online-only push to a dealer-led model, grew its sales network outside China and shut its 30 Chinese retail sites. U.S. tariffs have squeezed margins and forced production and supply-chain changes, while Polestar has depended on majority owner Geely — which also controls Volvo Cars — for funding, including a $900 million financing package in December. (Reuters)

Friday’s report gives a top-line read, but not much on profits. Traders will want to hear on Feb. 18 what management thinks it can do on gross margin, cash burn and the cost of building out that Europe-heavy push.

But the setup can turn fast. Any stumble in deliveries, a fresh tariff squeeze, or slower dealer ramp-up could shove the focus back to liquidity and dilution rather than sales momentum.

After Friday’s drop, the stock is still well above the $1 listing threshold that once hung over it, yet the swings underline how sensitive the name remains to headlines and guidance.

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Intel stock jumps nearly 10% after Trump praise; earnings in focus
Previous Story

Intel stock jumps nearly 10% after Trump praise; earnings in focus

Micron stock jumps 5% on Moody’s upgrade, Mizuho target hike as memory bets return
Next Story

Micron stock jumps 5% on Moody’s upgrade, Mizuho target hike as memory bets return

Go toTop